Revance Therapeutics (STU:RTI) Operating Cash Flow per Share : €-1.83 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Operating Cash Flow per Share?

Revance Therapeutics's operating cash flow per share for the three months ended in Sep. 2024 was €-0.36. Revance Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.83.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 0.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Revance Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

STU:RTI' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -8 Med: -0.95 Max: 25
Current: 5.9

During the past 13 years, Revance Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 25.00% per year. The lowest was -8.00% per year. And the median was -0.95% per year.

STU:RTI's 3-Year OCF Growth Rate is ranked better than
53.51% of 1198 companies
in the Biotechnology industry
Industry Median: 3.5 vs STU:RTI: 5.90

Revance Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Revance Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Operating Cash Flow per Share Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.20

-2.53

-2.90

-2.51

-2.35

Revance Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.55	-0.45	-0.66	-0.37	-0.36

Competitive Comparison of Revance Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Revance Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Price-to-Operating-Cash-Flow falls into.

Revance Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Revance Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-198.599	/	84.599
	=	-2.35

Revance Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )	=	Cash Flow from Operations (Q: Sep. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
	=	-37.022	/	104.213
	=	-0.36

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.83

Revance Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

RVNC:USA

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines